Pooled Analysis of Phosphatidylinositol 3-kinase Pathway Variants and Risk of Prostate Cancer
View/ Open
Author
Koutros, Stella
Schumacher, Fredrick R.
Hayes, Richard B.
Ma, Jing
Huang, Wen-Yi
Albanes, Demetrius
Canzian, Federico
Chanock, Stephen J.
Crawford, E. David
Diver, W. Ryan
Feigelson, Heather Spencer
Giovanucci, Edward
Haiman, Christopher A.
Henderson, Brian E.
Hunter, David J.
Kaaks, Rudolf
Kolonel, Laurence N.
Kraft, Peter
Marchand, Loïc Le
Riboli, Elio
Siddiq, Afshan
Stram, Daniel O.
Thomas, Gilles
Travis, Ruth C.
Thun, Michael J.
Yeager, Meredith
Berndt, Sonja I.
Published Version
https://doi.org/10.1158/0008-5472.CAN-09-3575Metadata
Show full item recordCitation
Koutros, S., F. R. Schumacher, R. B. Hayes, J. Ma, W.-Y. Huang, D. Albanes, F. Canzian, et al. 2010. “Pooled Analysis of Phosphatidylinositol 3-Kinase Pathway Variants and Risk of Prostate Cancer.” Cancer Research 70 (6): 2389–96. https://doi.org/10.1158/0008-5472.can-09-3575.Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, including cellular proliferation and intracellular trafficking, and may affect prostate carcinogenesis. Thus, we explored the association between single-nucleotide polymorphisms (SNP) in PI3K genes and prostate cancer. Pooled data from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium were examined for associations between 89 SNPs in PI3K genes (PIK3C2B, PIK3AP1, PIK3C2A, PIK3CD, and PIK3R3) and prostate cancer risk in 8,309 cases and 9,286 controls. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. SNP rs7556371 in PIK3C2B was significantly associated with prostate cancer risk [OR(per) (allele), 1.08 (95% CI, 1.03-1.14); P(trend) = 0.0017] after adjustment for multiple testing (P(adj) = 0.024). Simultaneous adjustment of rs7556371 for nearby SNPs strengthened the association [OR(per) (allele), 1.21 (95% CI, 1.09-1.34); P(trend) = 0.0003]. The adjusted association was stronger for men who were diagnosed before the age of 65 years [OR(per) (allele), 1.47 (95% CI, 1.20-1.79); P(trend) = 0.0001] or had a family history [OR(per) (allele) = 1.57 (95% CI, 1.11-2.23); P(trend) = 0.0114], and was strongest in those with both characteristics [OR(per) (allele) = 2.31 (95% CI, 1.07-5.07), P-interaction = 0.005]. Increased risks were observed among men in the top tertile of circulating insulin-like growth factor-I (IGF-I) levels [OR(per) (allele) = 1.46 (95% CI, 1.04-2.06); P(trend) = 0.075]. No differences were observed with disease aggressiveness (Gleason grade = 8 or stage T(3)/T(4) or fatal). In conclusion, we observed a significant association between PIK3C2B and prostate cancer risk, especially for familial, early-onset disease, which may be attributable to IGF-dependent PI3K signaling. Cancer Res; 70(6); 2389-96. (C)2010 AACR.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292589
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)